Institutional Usage of Ferric Pyrophosphate Citrate (FPC) Delivered Via Dialysate in Reducing Erythropoiesis Stimulating Agents (ESAs) and IV Iron Cost

Autor:	Naveed Masani, Shan Wang, Louis Dellafera, Brian Malone, Meredith Akerman, Paula Dutka, Lameesa Dhanani
Rok vydání:	2021
Předmět:	Pharmacology Nephrology medicine.medical_specialty business.industry Pharmacy Dialysis patients Multiple factors Original Research Articles Internal medicine medicine Iron deficient FERRIC PYROPHOSPHATE CITRATE Erythropoiesis Pharmacology (medical) Hemoglobin business
Zdroj:	Hosp Pharm
ISSN:	1945-1253 0018-5787
Popis:	Dialysis patients are often iron deficient due to a multiple factors. Ferric pyrophosphate citrate is a complex iron salt that can be given via dialysate allowing maintenance of hemoglobin (Hgb) concentration and iron balance while reducing the need for IV iron. The purpose of this study is to perform a cost evaluation of FPC and the effect it has on lowering the dose/use of ESAs and IV iron therapy. This study reviewed the same 100 hemodialysis patient’s charts before and after the use of FPC. The data points that were collected and analyzed are as follows: hemoglobin, ferritin levels, average weekly ESA dosing, and IV iron replacement therapy dose. Out of 100 patients, there was no statistical difference in the average hemoglobin, ferritin, and iron saturation levels observed in the patients before and after FPC use. The average weekly dose of darbepoetin alfa per patient was 52.74 μg before the FPC group compared to 39.27 μg in the post FPC group ( P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ae17289616b5673bf1af3cc8bcf5b9f https://doi.org/10.1177/00185787211032363 Zobrazit plný text záznamu